The fundamental role of altered epigenetic modification patterns in tumorigenesis establishes epigenetic regulatory enzymes as important targets for cancer therapy. Over the past few years, several drugs with an epigenetic activity have received approval for the treatment of cancer patients, which has led to a detailed characterization of their modes of action. The results showed that both established drug classes, the histone deacetylase (HDAC) inhibitors and the DNA methyltransferase inhibitors, show substantial limitations in their epigenetic specificity. HDAC inhibitors are highly specific drugs, but the enzymes have a broad substrate specificity and deacetylate numerous proteins that are not associated with epigenetic regulation. Similarly, the induction of global DNA demethylation by non-specific inhibition of DNA methyltransferases shows pleiotropic effects on epigenetic regulation with no apparent tumor-specificity. Second-generation azanucleoside drugs have integrated the knowledge about the cellular uptake and metabolization pathways, but do not show any increased specificity for cancer epigenotypes. As such, the traditional rationale of epigenetic cancer therapy appears to be in need of refinement, as we move from the global inhibition of epigenetic modifications toward the identification and targeting of tumor-specific epigenetic programs. Recent studies have identified epigenetic mechanisms that promote self-renewal and developmental plasticity in cancer cells. Druggable somatic mutations in the corresponding epigenetic regulators are beginning to be identified and should facilitate the development of epigenetic therapy approaches with improved tumor specificity.
Introduction
The traditional rationale for the development of epigenetic cancer drugs is based on the observation that many tumors show an aberrant epigenetic modification pattern. These tumor-specific epigenetic alterations or epigenetic mutations, affect a variety of cancer-related genes. The most prominent example for epimutations is provided by the widely observed epigenetic silencing of tumor suppressor genes that is closely associated with promoter hypermethylation (Esteller, 2007; Jones and Baylin, 2007) . It has long been known that DNA methyltransferase inhibitors can effectively induce DNA demethylation and phenotypic changes related to the reactivation of epigenetically silenced genes (Jones and Taylor, 1980) . These findings were later adapted to the targeting of epigenetic mutations in cancer and thus established the fundamental concept of epigenetic cancer therapy (Egger et al., 2004) .
Research over the past decade has shown that epigenetic regulation occurs on several mechanistic levels, including DNA methylation, covalent histone modifications and small regulatory RNAs (Esteller, 2007; Jones and Baylin, 2007) . Thus, in addition to DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors have also contributed to shape epigenetic cancer therapy. Altogether, there are currently four FDA-approved drugs with an epigenetic mode of action: the DNA methyltransferase inhibitors 5-azacytidine (Vidaza) and decitabine (2 0 -deoxy-5-azacytidine, Dacogen) and the HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, Zolinza) and romidepsin (Istodax). Various additional DNMT and HDAC inhibitors are currently being evaluated in preclinical studies and in clinical trials. However, there are currently no clinical trials with drug candidates directed against other epigenetic targets. This situation warrants a detailed discussion of DNMT and HDAC inhibitors before novel approaches towards an epigenetic therapy of cancer are considered.
5-Azacytidine and decitabine have shown significant clinical benefit in the treatment of myelodysplastic syndrome (Silverman et al., 2002; Kantarjian et al., 2006) and are also used for the treatment of myeloid leukemias. Both drugs are particularly effective when administered at low doses, which are sometimes below 10% of their maximum tolerated doses (Issa and Kantarjian, 2009 ). These conditions are generally assumed to maximize DNA demethylation responses, and several studies have confirmed that drug-induced DNA demethylation occurs in patients (Issa et al., 2005; Mund et al., 2005; Soriano et al., 2007; Stresemann and Lyko, 2008) . However, a direct link between DNA demethylation and clinical responses has not been demonstrated yet and there are currently no established DNA methylation biomarkers that accurately predict patient responses (Fandy et al., 2009) . This remains as an important challenge that is related to the complex mode of action of azanucleosides (see below) and that will have to be addressed in future studies to firmly establish clinical proof-of-concept for epigenetic therapy with these drugs.
The HDAC inhibitors SAHA and romidepsin are approved for the treatment of cutaneous T-cell lymphoma (Olsen et al., 2007; Piekarz et al., 2009) . Numerous additional HDAC inhibitors are currently undergoing clinical testing. The high number of developmental drugs is related to the excellent druggability of the HDAC enzyme family, which permits the development of potent isoenzyme-specific inhibitors (Bolden et al., 2006) . It is important to notice that histone deacetylation has been shown to synergistically interact with DNA methylation in the epigenetic silencing of cancer genes (Cameron et al., 1999) . This observation has also provided the scientific rationale for various clinical trials with combinations of DNMT and HDAC inhibitors. Somewhat surprisingly, these studies have yet to reveal synergistic clinical effects, which might again be related to complexities in the drugs' modes of action that are only beginning to become elucidated (see below).
Are HDAC inhibitors epigenetic drugs?
The important role of HDAC inhibitors in current concepts of epigenetic cancer therapy is often interpreted to reflect a high specificity of HDACs for histone substrates. However, similar to the situation with DNA methyltransferase inhibitors, a direct link between druginduced histone hyperacetylation and clinical responses remains to be established. It is now becoming increasingly clear that the enzymatic activity of HDACs is not restricted to histone proteins, and treatment of human cancer cell lines with highly specific HDAC inhibitors can induce hyperacetylation of 1750 proteins (Choudhary et al., 2009) . This finding strongly suggests that nonhistone proteins constitute the large majority of HDAC substrates. In addition, these studies also suggest that the complexity and functional significance of the human protein acetylome are similar to the more established protein phosphorylome. It is conceivable that these modification signatures have combinatorial roles in regulating the biological activity of proteins (Sims and Reinberg, 2008) . Drug-induced alterations of nonhistone protein modification signatures could therefore have a major role in the pharmacological responses to HDAC inhibitors (Xu et al., 2007) .
A prominent example for this notion is provided by the identification of HR23B, a protein that is involved in DNA repair and in proteasomal targeting of ubiquitinylated substrates, and that has a major role in regulating the sensitivity of cancer cells to HDAC inhibitors (Fotheringham et al., 2009) . Efficient induction of apoptosis by HDAC inhibitors was closely associated with reduced proteasomal activity and required the presence of HR23B. These data suggest that HDAC inhibitors target aberrant proteasome activity in cancer cells, which is possibly mediated by hyperacetylation of proteasome-associated non-histone proteins.
Moreover, when yeast cells were incubated in the presence of the HDAC inhibitor valproic acid, the drug specifically counteracted the activation of the ATRmediated DNA damage checkpoint response (Robert et al., 2011) . Surprisingly, the effect on DNA damage repair involved the degradation of key recombination proteins by autophagy (Robert et al., 2011) . These observations were explained by a model where protein acetylation marks DNA recombination proteins for transport to the vacuole and subsequent degradation, and where deacetylation of these factors is required for their stabilization in subnuclear compartments with severely damaged DNA. In this model, HDAC inhibitors would affect major oncological pathways (DNA damage response and autophagy) without invoking any effects on epigenetic gene regulation. Altogether, these findings further illustrate why HDAC inhibitors should not be considered as specific epigenetic drugs. It is possible (although not proven) that targeting of other histone modifying enzymes, like histone methyltransferases and histone demethylases, might permit a higher degree of epigenetic specificity (see below).
Epigenetic cancer therapy with DNMT inhibitors
The most frequently used epigenetic drugs are the cytosine derivatives 5-azacytidine and decitabine. Both drugs are undergoing a series of metabolic activation steps before they can become incorporated into nucleic acids (Figure 1 ). Incorporation of azacytosine bases into DNA and RNA triggers a multitude of stress and damage signaling pathways (Hollenbach et al., 2010) , but also induces the formation of covalent adducts between DNA and DNA methyltransferases. This covalent trapping results in the depletion of the enzymes and thus causes a global reduction of DNA methylation (Stresemann and Lyko, 2008) . A global reduction of DNA methylation has been shown to have antitumoral effects in a mouse model for intestinal tumorigenesis (Laird et al., 1995) . In this study, a combination of hypomorphic alleles for the DNA methyltransferase 1 gene caused a significant reduction in the size and number of intestinal polyps. To date, these observations still represent the most important proof-of-concept data for the antitumoral effects of global DNA demethylation.
It is generally assumed that the therapeutic benefit of global DNA demethylation is related to the demethylation and reactivation of aberrantly silenced genes. However, global demethylation is not selective for cancer-specific methylation marks and epigenetic side effects could severely curtail the specificity of demethylation therapy (see below). It is likely that individual DNA methyltransferases, like DNMT3B, have specific roles in the establishment and/or maintenance of cancerspecific DNA methylation changes (Linhart et al., 2007) .
Thus, the availability of enzyme-specific DNMT inhibitors would facilitate the targeting of cancer-specific epigenetic alterations. Small molecules that selectively inhibit individual DNMT enzymes in biochemical assays have been described recently (Kuck et al., 2010) and the development of enzyme-specific inhibitors thus appears feasible. However, even though we have seen a rapid increase in the number of candidate DNMT inhibitors over the past few years, the epigenetic potency of 5-azacytidine and decitabine presently remains unmatched (Chuang et al., 2005; Stresemann et al., 2006; MedinaFranco et al., 2011) . Moreover, the known smallmolecule DNMT inhibitors would require a substantial amount of preclinical development before competitive clinical candidates are likely to emerge. Thus, additional screening efforts will be required for the identification of small-molecule scaffolds with a high potency in the inhibition of specific DNMT enzymes.
Because of the inherently low specificity of azanucleoside drugs, enzyme-specific DNMT inhibitors will also be important for unambiguously establishing clinical proof-of-concept for demethylation therapies. It is important to realize that a causal link between druginduced demethylation and therapeutic responses to 5-azacytidine or decitabine has not been established yet. A clinical relevance of the epigenetic effects is currently mostly supported by characteristic details in the progression of clinical responses in cancer patients: for example, both drugs trigger delayed hematologic responses. This contrasts the responses observed with cytarabine, a chemically related drug that has no known epigenetic activity and induces immediate cytotoxic responses (Issa and Kantarjian, 2009 ). Altogether, these findings suggest that nucleoside DNMT inhibitors have genuine epigenetic activity in patients, but important details remain to be established.
Metabolic activation and cellular transport of DNMT inhibitors
The continued clinical development of azanucleosides requires detailed knowledge of the drugs' cellular metabolism. Both drugs utilize different pathways for their intracellular metabolization, as the azacytosine ring is bound to ribose in 5-azacytidine and to deoxyribose in decitabine. In this context, three enzymes appear to be particularly relevant: (1) deoxycytidine kinase (dCyd kinase), which catalyzes the initial ratelimiting step in the synthesis of the monophosphorylated form of decitabine; (2) uridine-cytidine kinase (Urd-Cyd kinase), which is assumed to be responsible for the monophosphorylation of 5-azacytidine; and (3) ribonucleotide reductase, which reduces 5-azacytidine diphosphate to 5-azadeoxycytidine diphosphate (Figure 1) .
Deficiencies in dCyd kinase activity have long been linked to decitabine resistance. This was confirmed by the selection and characterization of decitabine-resistant rat leukemic cell lines that revealed mutations in the dCyd kinase gene (Stegmann et al., 1995) . Similar results were obtained in more recent studies with human cancer cells, where decitabine sensitivity could be restored by transfection of the wild-type dCyd kinase (Qin et al., 2009) . dCyd kinase has also been used to predict in vivo sensitivity and resistance to other cytidine analogs, such as gemcitabine and cytarabine, in patients (Flasshove et al., 1994; Kroep et al., 2002) . Taken together, these results clearly imply dCyd kinase as a key enzyme in the metabolic activation of decitabine and a potentially important factor in clinical decitabine resistance.
As outlined above, 5-azacytdine is metabolized by a distinct biochemical pathway, and it is assumed that the monophosphorylation step is catalyzed by Urd-Cyd kinase. This assumption is based on the observation that both uridine and cytidine inhibit the phosphorylation Figure 1 Cellular pathways for the metabolic activation of DNMT inhibitors. Members of the hENT, hCNT, the proton oligopeptide cotransporter familiy (SLC15) and the SLC22 family of organic cation and anion transporters are known to mediate the uptake of nucleoside analogs. Inside the cells, 5-azacytidine (5-aza-CR) and decitabine (5-aza-2 0 -deoxycytidine; 5-aza-dCR) are metabolized to nucleotides by different enzymes before incorporation into DNA and RNA. Metabolic intermediates can also be effluxed from the cells by members of the ABC family. Several enzymes are a potential source of drug resistance and are marked in red.
Epigenetic cancer therapy M Rius and F Lyko and nucleic acid incorporation of 5-azacytidine with a consequent reduction of its toxicity in leukemia cell lines (Li et al., 1970) . However, Urd-Cyd kinase failed to phosphorylate 5-azacytidine in biochemical assays (Van Rompay et al., 2001) , and the enzyme has not been demonstrated to be rate-limiting in the metabolism of 5-azacytidine. As such, additional work will be required to experimentally confirm the role of Urd-Cyd kinase in the phosphorylation of 5-azacytidine and to further characterize the biochemical pathway(s) for the metabolic activation of 5-azacytidine.
Ribonucleotide reductase is another critical enzyme and represents an important link between the metabolism of 5-azacytidine and decitabine. This enzyme enables the metabolites of 5-azacytidine to become incorporated into DNA and is thus rate limiting for the synthesis of deoxyribonucleotides from ribonucleotides ( Figure 1) . Importantly, the enzyme only reduces a fraction of 5-azacytidine metabolites to deoxycytidine metabolites, whereas a major part is phosphorylated and incorporated into RNA (Li et al., 1970) . This fractional conversion of 5-azacytidine to deoxycytidine metabolites has also been used to explain the differential effects of 5-azacytidine and decitabine in human cancer cell lines (Hollenbach et al., 2010) . For example, decitabine often causes DNA hypomethylation at lower concentrations, whereas 5-azacytidine has greater effects on reducing cell viability and protein synthesis (Hollenbach et al., 2010; Hagemann et al., 2011) . Further insight could come from the combined use of azanucleosides with ribonucleotide reductase inhibitors. Initial studies have suggested that DNA demethylation by both 5-azacytidine and decitabine could be inhibited by the ribonucleotide reductase inhibitor hydroxycarbamide (Choi et al., 2007) , and it will be important to investigate the effect of drug treatment on the nucleotide pool and on the resulting effects on cell cycle regulation.
Apart from their metabolic activation, the cellular transport across the plasma membrane represents an additional, important factor in the response of cancer cells to azanucleoside drugs. In particular, reduced uptake into the cells or increased efflux from the cells results in reduced intracellular drug levels and, consequently, in the development of drug resistances. Several families of membrane transporters have been recognized to have a role in the transport of nucleosides and nucleoside analogs across the plasma membrane in human cells (Pastor-Anglada et al., 2005; Damaraju et al., 2009; Huber-Ruano and Pastor-Anglada, 2009 ). These include the SLC28 and SLC29 families encoding the concentrative and equilibrative nucleoside transporters, respectively (hCNT/SLC28 and hENT/SLC29) and the ATP-binding cassette (ABC) family (Figure 1) .
The hCNT and hENT proteins represent the bestknown nucleoside transporters. While hCNTs mediate the uptake of nucleosides against a concentration gradient and in a Na þ -dependent manner, hENTs facilitate the transport of nucleosides in a bidirectional manner (Huber-Ruano and Pastor-Anglada, 2009). Compared with hENTS, hCNTs have a higher affinity for the substrates, but are mostly expressed in specialized epithelial tissues. Gene expression analyses that demonstrated a positive correlation between hENT1 expression and 5-azacytidine potency in human cancer cell lines provided a first indication for an important role of hENTs in 5-azacytidine uptake (Huang et al., 2004) . Furthermore, low expression levels of hENT1 and hENT2 were detected in cells resistant to decitabine (Qin et al., 2009) . As hENT transporters show ubiquitous expression, they can have a major role in the sensitivity and resistance of cancer cells to azanucleoside DNMT inhibitors. The ability of hCNT transporters to mediate cellular uptake of 5-azacytidine and decitabine (Rius et al., 2009) probably becomes more relevant for the treatment of epithelial cell-derived tumors, where the expression levels of hCNT proteins can be higher.
In addition to the hCNT and hENT proteins, several members of the ABC superfamily and particularly the members of the ABCC subfamily have been described to mediate the cellular efflux of nucleoside drug metabolites (Cole and Deeley, 2006) . However, little is known about specific transporters that mediate the efflux of 5-azacytidine and decitabine metabolites from cells. At present, only ABCC4 has been identified as an efflux pump for 5-azacytidine . Further studies are required because the ABC family represents a well-established factor in cancer drug resistance (Leonard et al., 2003) .
Lastly, the efficacy of 5-azacytidine and decitabine is also influenced by their plasma stability. In this context, cytidine deaminase (CDA), an enzyme involved in pyrimidine salvaging, has a major role. The enzyme catalyzes the hydrolytic deamination of (deoxy-)cytidine to (deoxy-)uridine and is also able to deaminate 5-azacytidine and decitabine to 5-azauridine and 5-aza-2 0 -deoxyuridine. Cytidine deaminase is ubiquitous in the human body and represents an important determinant for the biotransformation rates of cytarabine and gemcitabine, two cytidine analogs that are closely related to azanucleosides (Bhatla et al., 2009; Maring et al., 2010; Parmar et al., 2011) .
The increasing knowledge of the mechanisms mediating cellular drug uptake and metabolization has also fueled the development of improved azanucleoside derivatives. This is exemplified by S110 and CP-4200, two second-generation azanucleoside drugs (Figure 2 ). S110 is a dinucleotide of decitabine and deoxyguanidine, and is highly resistant to cytidine deaminase (Yoo et al., 2007) . CP-4200 is an elaidic acid ester of 5-azacytidine, which utilizes a modified and potentially less selective transport uptake mechanism (Brueckner et al., 2010) . Importantly, both drugs have retained robust demethylating activity, despite their extensive chemical modifications (Yoo et al., 2007; Brueckner et al., 2010) . In addition, CP-4200 also causes widespread DNA demethylation and reactivation of tumor suppressor genes under conditions where inhibition of hENTdependent drug transport completely blocked the demethylating effects of 5-azacytidine (MR and FL, unpublished data). Both CP-4200 and S110 have shown significant in vivo activity in mouse tumor models (Brueckner et al., 2010; Chuang et al., 2010) , which further illustrates the potential of the azacytosine scaffold for continued preclinical development. Importantly, the development of chemically modified azacytosine derivatives might also allow the targeting of tumor entities that are insensitive to 5-azacytidine and decitabine.
Epigenetic side effects of global DNA demethylation
Apart from the hypermethylation of cancer genes, human cancer cells are also characterized by an overall DNA hypomethylation (Ehrlich, 2002) . Genomic hypomethylation has long been associated with genomic instability and could thus represent a tumor-promoting epigenetic alteration. As the established DNA methyltransferase inhibitors show no specificity for tumor suppressor genes but rather affect epigenetic modifications globally, their ability to induce genomic instability remained an important safety issue. Indeed, mouse models with reduced levels of Dnmt1 and correspondingly reduced levels of genome-wide DNA methylation showed a high incidence of lymphomas, which was accompanied by genetic instability Gaudet et al., 2003) . Further analyses in this model suggested that DNA hypomethylation causes the activation and transposition of endogenous retroviral elements (Howard et al., 2008) . This finding also implied that the activation of (normally silent) repetitive elements might be a particularly important factor in the cellular response to global DNA demethylation.
More recently, the consequences of global DNA demethylation on the epigenetic regulation of repetitive elements were further characterized in human cancer cells (Weber et al., 2010; Wolff et al., 2010) . It was shown that the demethylation of a highly methylated LINE-1 antisense promoter in an intron of the cMet proto-oncogene results in the induction of an illegitimate cMet transcript, which is associated with reduced cMet protein expression and decreased cMet receptor signaling. These findings provide an important example for abnormal transcriptional regulation induced by the demethylation of repetitive elements and suggest that many genomic loci might be subject to the epigenetic side effects of global DNA demethylation (Lizardi, 2010) .
Recent epigenomic studies have also shown that epigenetic gene silencing by DNA methylation and collaborating epigenetic mechanisms can be observed at numerous developmental genes and in normal cells (Mohn and Schubeler, 2009) . For example, differentiation-associated genes are methylated in mouse and human hematopoietic progenitor cells and become demethylated during differentiation (Ji et al., 2010; Bocker et al., 2011) . A functional role of DNA methylation in the differentiation of adult progenitor cells is further supported by the observation that hematopoietic stem cells from mice with reduced DNA methyltransferase 1 activity failed to suppress key differentiation genes and lost their ability to differentiate into lymphoid progeny (Broske et al., 2009) . While the same study also revealed a therapeutic potential of global DNA hypomethylation for restricting the selfrenewal capacity of leukemia stem cells, the data clearly demonstrates that DNA methylation is required to protect normal hematopoietic stem cells from lineage restriction.
In a more general sense, these studies illustrate that tightly controlled DNA demethylation is an important factor in cellular differentiation (Figure 3) . The findings imply that epigenetic drugs that induce global DNA demethylation and/or the global loss of collaborating histone modifications could adversely affect the functionality of adult progenitor cell populations in patients. Moreover, numerous large blocks with significant hypomethylation were described in colon cancer methylomes (Hansen et al., 2011) . These blocks showed increased gene expression variation, which suggested that a further decrease in DNA methylation beyond the normal levels of differentiated cells might induce phenotypic variability (Figure 3) . Drugs that induce global DNA hypomethylation could thus promote oncogenic transformation in cancer patients (Hansen et al., 2011) , and it appears critical that more specific epigenetic drugs become identified and developed. This might not be achievable through the inhibition of DNA methyltransferases and would therefore require the targeting of other epigenetic factors and pathways.
A new rationale for epigenetic cancer therapy: targeting the epigenetic plasticity of cancer cells When the traditional rationale for epigenetic cancer therapy was first developed, it was assumed that hypermethylation-associated gene silencing is only Figure 2 Second-generation DNMT inhibitors. A second-generation of nucleoside DNMT inhibitors has been developed recently to increase drug stability and to overcome transport-related drug resistance. The dinucleotide derivative of decitabine, S110, is resistant to the hydrolytic cleavage by the plasma cytidine deaminase, in contrast to the parental drug decitabine, which is rapidly deaminated in blood. The elaidic acid ester of 5-azacytidine, CP-4200, enters into cells through a hENTindependent mechanism, thus overcoming transporter-related drug resistance. Chemical structures used for the modification of the azacytosine scaffold are marked in blue.
Epigenetic cancer therapy M Rius and F Lyko observed in the context of epigenetic mutations. However, it is now clear that hypermethylation-associated gene silencing also has an important role in the regulation of developmental genes and therefore does not represent a cancer-specific epigenetic alteration. Consequently, the traditional rationale for epigenetic cancer therapy requires further development to provide sufficient tumor selectivity for therapeutic success.
A higher degree of specificity could be achieved if epigenetic cancer therapy could be directed against cancer-specific epigenetic modification patterns. While many details remain to be resolved, several studies have provided evidence for cancer-specific epigenetic pathways. For example, chromosomal translocations affecting the MLL gene cause mixed lineage leukemia that is characterized by highly defined gene expression changes associated with aberrant H3K79 methylation (Bernt et al., 2011) . In agreement with this notion, a potent small-molecule inhibitor of the H3K79 methyltransferase DOT1L selectively killed cancer cells that harbored the MLL gene translocation (Daigle et al., 2011) ; thus providing a compelling paradigm for epigenetic therapy with a very high degree of cancer specificity.
It has also been shown that genes affected by de novo DNA methylation during tumorigenesis are pre-marked by histone H3 lysine 27 trimethylation, suggesting that this chromatin modification functions as an instructive mechanism in the establishment of cancerspecific DNA methylation patterns Schlesinger et al., 2007; Widschwendter et al., 2007) . Of note, H3K27 trimethylation is also an important component of 'bivalent' chromatin structures that are defined by the presence of both activating H3K4 trimethylation and repressive H3K27 trimethylation (Bernstein et al., 2006) . Bivalent chromatin structures represent a defining molecular characteristic of embryonic stem cells and the relationship between H3K27 trimethylation, and de novo DNA methylation is assumed to reflect the presence of a stem cell-like epigenetic program in cancer cells (Ohm and Baylin, 2007) . In agreement with this notion, a recent analysis also identified bivalent chromatin structures in human tumor samples (Aiden et al., 2010) .
An attractive strategy towards the development of more specific epigenetic cancer therapies thus resides in the targeting of the enzymes that instruct cancer-specific de novo methylation and/or cancer stem cell phenotypes. An intriguing candidate is the histone H3 lysine 27 methyltransferase EZH2. This enzyme, together with its closely related paralog EZH1, is critical for stem cell identity and for the establishment of H3K27 methylation marks within bivalent chromatin structures of embryonic stem cells (Shen et al., 2008) . Several studies have described overexpression of EZH2 in human cancers, including prostate and breast cancer, as well as in lymphoma (Varambally et al., 2002; Simon and Lange, 2008) . Importantly, while cancer genome sequencing approaches detected inactivating EZH2 mutations in myeloid leukemias (Ernst et al., 2010; Nikoloski et al., 2010) , they also uncovered specific heterozygous point mutations of EZH2 in lymphomas (Morin et al., 2010) . These point mutations cause an enhanced capacity of EZH2 to di and trimethylate H3K27 (Sneeringer et al., 2010) and could thus drive the establishment of cancerspecific epigenetic programs. Intriguingly, the mutant EZH2 enzyme appears to be druggable, which should allow the development of potent inhibitors with a high degree of cancer specificity for the treatment of patients that carry the corresponding mutation.
Additional cancer-specific epigenetic drug targets should be identified through ongoing studies that investigate the mechanisms underlying the phenotypic plasticity of cancer cells. These approaches will identify the factors that establish and maintain the embryonic chromatin environment conductive to self-renewal and developmental plasticity in cancer cells. Successful targeting of the corresponding enzymes would result in reduced proliferation and reduced developmental plasticity, thus limiting both tumor growth and the selfrenewal capacity of tumor stem cells (Figure 4) . Apart from EZH2/EZH1, candidates should include the as yet unknown enzyme(s) required for H3K4 trimethylation in stem cells. The TET enzymes represent additional factors that are associated with epigenetic regulation and cell fate determining mechanisms. These enzymes catalyze the hydroxylation and further modification of methylated DNA and probably have an important role in the demethylation of DNA . TET proteins are associated with bivalent chromatin domains and have an important role in targeting EZH2 to chromatin (Williams et al., 2011; Wu et al., 2011) . The wealth of data generated by cancer genome and epigenome-sequencing projects is very likely to identify additional somatic mutations in epigenetic regulators that have important roles in the establishment and maintenance of cancer-specific epigenetic modification patterns. Some of these mutations will likely be Figure 3 DNA demethylation in cellular differentiation and oncogenic transformation. In adult progenitor cells, DNA methylation is found in differentiation-associated genes, preventing cells from differentiation. Demethylation causes the activation and expression of differentiation genes. Further demethylation has been associated with increasing gene expression variability and increased phenotypic variability of cancer cells (Hansen et al., 2011) . The use of hypomethylating drugs in cancer patients may thus interfere with normal epigenetic regulation in adult progenitor cells and/or induce a tumor-promoting epigenetic program. druggable and thus give rise to novel epigenetic drug candidates.
Conclusions and perspective
The field of epigenetics has spawned four approved cancer drugs, thus underscoring its great promise for cancer therapy. However, the increasing use of these drugs, both in the laboratory and in the clinical practice, also identified important limitations. These limitations are largely defined by a lack of specificity on several levels, including drug specificity, substrate specificity of the targeted enzymes and cancer specificity of the targeted epigenetic pathways. At the same time, the azacytosine scaffold has shown unmatched potency in the inhibition of DNA methylation. This has renewed the scientific interest in the cellular uptake and metabolization pathways of azanucleosides and has allowed the development of second-generation DNMT inhibitors.
More importantly, however, the genomic and epigenomic profiling of tumors is currently revolutionizing our molecular understanding of cancer and allows fundamentally novel insights into the epigenetic programs driving tumorigenesis. Several mutations have been identified in factors associated with DNA methylation (TET2, IDH1/2, DNMT3A) and could conceivably increase or decrease global methylation levels. It is possible that these mutations could serve as patient stratification biomarkers for the treatment with demethylating drugs. Additional mutations include druggable somatic mutations in histone modification factors that are connected to the developmental plasticity of cancer cells. Many additional epigenetic target candidates are likely to be discovered by combining data from cancer genome sequencing projects with data from corresponding epigenome sequencing projects. Careful characterization of these factors will allow the distinction between epigenetic drivers and passengers and will lead to the development of a diverse array of highly specific epigenetic drugs.
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